Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First in Human, Dose-Escalation Study of TORL-2-307-MAB in Participants With Advanced Cancer

NCT05159440 is registered in ClinicalTrials.gov with TORL Biotherapeutics, LLC as lead sponsor.

NCT NCT05159440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05159440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First in Human, Dose-Escalation Study of TORL-2-307-MAB in Participants With Advanced Cancer
Lead sponsor
TORL Biotherapeutics, LLC
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 20, 2022
Completion date
December 15, 2025
Enrollment
70 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, gastric cancer, gastroesophageal junction adenocarcinoma, pancreas cancer